Multiple myeloma (MM) is a malignant tumor of plasma cells. Although treatment options have expanded in recent years, relapsed or refractory disease after multiple lines of treatment remains a significant clinical challenge. On August 25,…
On August 25, 2026, the innovative drug Fanregratinib was approved by NMPA for adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) who have received prior systemic therapy and whose tumors harbor FGFR2 fusions…
On August 27, Johnson & Johnson announced that Icotrokinra had been approved by NMPA for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as pediatric…
On August 20, NMPA announced the approval of Licancopan Fumarate Capsules, a Class 1 innovative drug developed by Hengrui Pharma, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received…
On August 20, 2026, Anflekitug was approved in China as an innovative drug developed by Sunshine Guojian, providing a new IL-1β targeted treatment option for adults with acute gouty arthritis and further expanding the treatment…
Felzartamab is a CD38-targeting human monoclonal antibody, with Felzartamab approved for multiple myeloma in China and under clinical development for IgA nephropathy, primary membranous nephropathy, and kidney transplant antibody-mediated rejection. Recently, information published on the…
Tinengotinib approved for cholangiocarcinoma marks an important advance for patients with FGFR2 fusion or rearrangement-positive disease who have progressed after FGFR inhibitor therapy. As a China-developed multi-target kinase inhibitor, it is the first globally approved…
Recibokibart approved for GPP marks a major milestone in Generalized Pustular Psoriasis (GPP) treatment. Developed by Shanghai Huaota Biopharmaceutical Co., Ltd., this IL-36R monoclonal antibody was approved by the NMPA on July 29, 2026, for…
Insulin Sudelidec approved for type 2 diabetes in China following NMPA approval for adults with type 2 diabetes. Key Phase III studies demonstrated comparable glucose-lowering efficacy to insulin glargine, with lower hypoglycemia risks, expanding treatment…
Plozasiran now available in China marks a milestone for FCS patients, offering a new APOC3-targeted siRNA therapy to help lower triglyceride (TG) levels in adults with familial chylomicronemia syndrome. In July 2026, Sanofi announced that…
Ciprocopan approved in China as the world’s first once-daily oral Complement Factor B (CFB) inhibitor, bringing a new oral treatment option for patients with paroxysmal nocturnal hemoglobinuria (PNH). On July 23, 2026, China’s National Medical…
Oveporexton approved first in China, becoming the world’s first approved selective orexin receptor 2 (OX2R) agonist and the first therapy designed to target the underlying mechanism of Type 1 narcolepsy (NT1). On July 21, 2026,…
